Molecular markers are associated with early computed tomography ischemic changes;Marcadores moleculares asociados a signos precoces de isquemia en tomografía computarizada cerebral

Neurologia

Volumn 23, Issue 4, 2008, Pages 220-225

  Rodriguez Yanez M ^a   Castellanos, M ^b   Sobrino, T ^a   Blanco, M ^a   Nombela, F ^c   Rodriguez Gonzalez R ^a   Leira, R ^a   Serena, J ^b   Davalos A ^d   Castillo, Jose ^a,e  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e University Hospital of Santiago de Compostela   (Spain)

Author keywords

Computed tomography; Early sings; Glutamate; Interleukin 6; Ischemic stroke; Metalloproteinase 9; Molecular markers

Indexed keywords

GELATINASE B; GLUTAMIC ACID; INTERLEUKIN 6; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN EDEMA; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; EXCITOTOXICITY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PROGNOSIS; SCORING SYSTEM; STROKE;

AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 46049086248     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pulsinelli W. Pathophysiology of acute ischemic stroke. Lancet 1992;339:533-6.
2. Cipolla MJ, McCall AL, Lessov N, Porter JM, Montes H. Reperfusion decreases myogenic reactivity and alters middle cerebral artery function after focal cerebral ischemia in rats. Stroke 1997;28:176-80.
3. Castillo J, Rodríguez I. Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004;17(Suppl. 1):7-18.
4. Dávalos A, Castillo J, Álvarez-Sabín J, Secades JJ, Mercadal J, López S, et al. Oral citicoline in acute ischemic stroke. Stroke 2002;33:2850-7.
5. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245-51.
6. The National Institute of Neurological Disorders and Stroke r-tPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Eng J Med 1995;333:1581-7.
7. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
8. Von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997;205:327-33.
9. Wardlaw JM, Seymour J, Cairns J, Keir S, Lewis S, Sandercock P. Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke 2004;35:2477-83.
10. Pexman JH, Barber PA, Hill MD, Sevick RJ, Demchuk AM, Hudon ME, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR 2001;22:1534-42.
11. Barber PA, Demchuk AM, Zhang J, Buchan AM, for the ASPECTS Study Group. Validity and reliability of quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 2000;355:1670-4.
12. Castillo J, Dávalos A, Naviero J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996;27:1060-5.
13. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
14. Cote R, Battista RN, Wolfson C, Boucher J, Adam J, Hachinski V. The Canadian Neurological Scale: validation and reliability assessment Neurology 1989;39:638-43.
15. Castillo J, Dávalos A, Noya M. Progression of ischemic stroke and excitotoxic aminoacids. Lancet 1997;349:79-83.
16. Castillo J, Dávalos A, Naveiro J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996;27:1060-5.
17. Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A. Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci 1999;162:185-8.
18. Farrarese C, Mascarucci P, Zoia, Cavarretta R, Frigo M, Begni B, et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999;19:1004-9.
19. Rosenberg GA, Estrada EY, Dencoff JE. Matriz metalloproteinases and TIMPs are associated with blood-barrier opening after reperfusion in rat brain. Stroke 1998;29:2189-95.
20. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for matriz metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000;20:1681-9.
21. Von Kummer R, Holle R, Grzyska U, Hoffmann E, Jansen O, Petersen D, et al. Interobserver agreement in assessing early CT signs of middle cerebral artery infarction. AJNR Am J Neuroradiol 1996;17:1743-8.
22. Von Kummer R, Bourquain H, Bastianello S, Bozzao L, Manelfe C, Meier D, et al. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology 2001;219:95-100.
23. Dá;valos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke 1999;30:2631-6.
24. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, et al. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830-8.
25. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Cereb Blood Flow Metab 1998;18:583-609.
26. Castellanos M, Castillo J, García MM, Leira R, Serena J, Chamorro A, et al. Inflammation-mediated damage in progressing lacunar infarctions. A potential therapeutic target. Stroke 2002;33:982-7.
27. Grotta J, Chiu D, Lu M, Patel S, Levine S, Tilley BC, et al. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rt-PA. Stroke 1999;30:1528-33.